Zacks Investment Research
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
Vaxcyte (PCVX) has gained 12.8% over the past four weeks and Wall Street analysts project a mean price target of $117.3, indicating a potential 75.6% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets can be misleading and should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.